Gary Sender is currently President of Sender Consulting LLC and previously served as the Chief Financial Officer of Nabriva Therapeutics plc from 2016 until his retirement in 2021. Nabriva is a Nasdaq-listed biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Prior to joining Nabriva, he served as …
In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has applied his strategic and functional expertise across corporate development, commercial operations, manufacturing, and R&D to help build and scale a number of global public and private biopharmaceutical businesses. He currently serves as President and CEO of LENZ Therapeutics, a biopharmaceutical company with …
Mr. Duran served as iBio’s Vice President of Financial Planning and Analysis (FP&A) from April 2021-February 2023. In that capacity, he played a strategic role in the Company’s forecasting, business planning, management reporting, and business analytics activities. From 2016 to 2021, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary …
Mr. Banjak joins iBio with over 15 years’ experience in the biotechnology and contract research industries. He previously served as the first general counsel of both Istari Oncology and Dova Pharmaceuticals, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through a number of clinical and corporate …
Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an …